IDH1 and astrocytoma (excluding glioblastoma): To overcome this limitation, we conducted a 72 h treatment for mutant IDH1-R132H BT142 (astrocytoma) and TS603 (oligodendroglioma) cell lines with AGI5198, which specifically inhibits IDH1R132H enzyme activity disrupting D-2HG formation (Figure 1a).